Phreesia (Phreesia) Change In Receivables : $-11.2 Mil (TTM As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Phreesia Change In Receivables?

Phreesia's change in receivables for the quarter that ended in Jan. 2024 was $-7.8 Mil. It means Phreesia's Accounts Receivable increased by $7.8 Mil from Oct. 2023 to Jan. 2024 .

Phreesia's change in receivables for the fiscal year that ended in Jan. 2024 was $-11.2 Mil. It means Phreesia's Accounts Receivable increased by $11.2 Mil from Jan. 2023 to Jan. 2024 .

Phreesia's Accounts Receivable for the quarter that ended in Jan. 2024 was $62.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Phreesia's Days Sales Outstanding for the three months ended in Jan. 2024 was 60.39.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Phreesia's liquidation value for the three months ended in Jan. 2024 was $15.8 Mil.

Phreesia Change In Receivables Historical Data

The historical data trend for Phreesia's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia Change In Receivables Chart

Phreesia Annual Data

Trend

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Change In Receivables

Get a 7-Day Free Trial

-5.91

-6.62

-10.22

-11.13

-11.21

Phreesia Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Receivables	Get a 7-Day Free Trial															-7.04	-1.54	-0.83	-0.99	-7.84

Phreesia Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.2 Mil.

Phreesia (NYSE:PHR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Phreesia's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	62.88	/	95.005	*	91
=	60.39

2. In Ben Graham's calculation of liquidation value, Phreesia's accounts receivable are only considered to be worth 75% of book value:

Phreesia's liquidation value for the quarter that ended in Jan. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	87.52	-	118.877	+	0.75 * 62.88	+	0.5 * 0
=	15.8

Phreesia Change In Receivables Related Terms

Thank you for viewing the detailed overview of Phreesia's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Phreesia (Phreesia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

19P:Germany 19P:Germany

Address

1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803

Website

https://www.phreesia.com

Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.

Executives

Balaji Gandhi	officer: Chief Financial Officer	PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman	officer: General Counsel & Secretary	315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn	officer: SVP, Human Resources	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig	director, officer: Chief Executive Officer	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff	officer: See Remarks	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky	officer: SVP, Life Sciences	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts	officer: Chief Operating Officer	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg	officer: Principal Accounting Officer	BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis	director	C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson	director	C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen	officer: Chief Financial Officer	PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar	director	305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub	director	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill	10 percent owner	C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453